Zap-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (cll/sll)
AssigneeThe Government of the USA as represented by the Secretary of the Dept. of Health and Human Service
InventorsLouis M. Staudt, Andreas Rosenwald, Wyndham Wilson, Todd S. Barry, Adrian Wiestner
Life of this patent
Estimating the term…
Abstract
It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.
Claims22
A method of determining a predisposition to poor clinical outcome in a subject having chronic lymphocytic leukemia (CLL), comprising determining in a sample comprising B-cells from the subject whether one or more of the B-cells are ZAP-70 positive, wherein ZAP-70 positive B-cells indicate predisposition to poor clinical outcome.
A method of determining a predisposition to poor clinical outcome in a subject having chronic lymphocytic leukemia (CLL), comprising determining in a sample comprising B-cells from the subject whether one or more of the B-cells expresses a ZAP-70 polypeptide, wherein expression of the ZAP-70 polypeptide indicates predisposition to poor clinical outcome.
A method of determining a predisposition to poor clinical outcome in a subject having chronic lymphocytic leukemia (CLL), comprising determining in a sample comprising B-cells from the subject whether one or more of the B-cells are ZAP-70 positive, wherein the ZAP-70 comprises a ZAP-70 polypeptide of SEQ ID NO:
- 2, and wherein ZAP-70 positive B-cells indicates predisposition to poor clinical outcome.
A method of determining a predisposition to poor clinical outcome in a subject having chronic lymphocytic leukemia (CLL), comprising determining in a sample comprising B-cells from the subject whether one or more of the B-cells express a ZAP-70 polypeptide of SEQ ID NO:
- 2, wherein expression of the ZAP-70 polypeptide indicates predisposition to poor clinical outcome.
Dependencies are inferred from the claim text.